Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function

Clinical Transplantation

Volumn 28, Issue 4, 2014, Pages 479-486

  Bleskestad, Inger H ^a   Bergrem, Harald ^a   Leivestad, Torbjørn ^b   Hartmann, Anders ^b   Gøransson, Lasse G ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cardiovascular disease; Chronic kidney disease mineral and bone disorder; Kidney transplantation; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCIUM; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID; PARATHYROID HORMONE; PHOSPHATE; PREDNISOLONE; VITAMIN D; BIOLOGICAL MARKER;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; TIME TO TREATMENT; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; REGISTER; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

BIOMARKERS; CALCIUM; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84899094065     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12341     Document Type: Article

References (33)

1. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003: 42: 1050.
2. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999: 341: 1725.
3. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000: 11: 1735.
4. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007: 71: 31.
5. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008: 73: 1296.
6. Floege J, Kim J, Ireland E et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011: 26: 1948.
7. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998: 13: 2294.
8. Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006: 36(Suppl 2): 51.
9. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994: 46: 855.
10. Bover J, Canal C, Marco H, Fernandez-Llama P, Bosch RJ, Ballarin J. Diagnostic procedures and rationale for specific therapies in chronic kidney disease-mineral and bone disorder. Contrib Nephrol 2008: 161: 222.
11. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009: 113: S1.
12. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998: 13: 436.
13. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004: 19: 1281.
14. Goransson LG, Bergrem H. Renal transplant and secondary hyperparathyroidism. Scand J Urol Nephrol 2007: 41: 553.
15. Bleskestad IH, Bergrem H, Leivestad T, Goransson LG. Intact parathyroid hormone levels in renal transplant patients with normal transplant function. Clin Transplant 2011: 25: E566.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999: 130: 461.
17. Transplantation EEGoR. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.13 Analysis of patient and graft survival. Nephrol Dial Transplant 2002: 17(Suppl 4): 60.
18. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 2009: 87: 1040.
19. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007: 21: 558.
20. Roodnat JI, van Gurp EA, Mulder PG et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation 2006: 82: 362.
21. Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011: 22: 956.
22. Molnar MZ, Kovesdy CP, Mucsi I, Salusky IB, Kalantar-Zadeh K. Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. Clin J Am Soc Nephrol 2012: 7: 1859.
23. Picton ML, Moore PR, Mawer EB et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000: 58: 1440.
24. Mac Way F, Lessard M, Lafage-Proust MH. Pathophysiology of chronic kidney disease-mineral and bone disorder. Joint Bone Spine 2012: 79: 544.
25. Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011: 15: 797.
26. Hernandez D, Rufino M, Bartolomei S et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005: 67: 2015.
27. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005: 5: 1934.
28. Brandenburg VM, Jahnen-Dechent W, Ketteler M. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation. Kidney Int Suppl 2009: 114: S26.
29. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004: 15: 770.
30. Weiner DE, Carpenter MA, Levey AS et al. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 2012: 12: 2437.
31. Aalten J, Hoogeveen EK, Roodnat JI et al. Associations between pre-kidney-transplant risk factors and post-transplant cardiovascular events and death. Transpl Int 2008: 21: 985.
32. Natoli JL, Boer R, Nathanson BH et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis BMC Nephrol 2013: 14: 88.
33. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011: 305: 1119.